These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K Digestion; 2020; 101(1):60-65. PubMed ID: 31801131 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410 [TBL] [Abstract][Full Text] [Related]
5. Unusual case of immune-related colitis. Issa M; Milioglou I BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978598 [TBL] [Abstract][Full Text] [Related]
6. Cascade of immunologic adverse events related to pembrolizumab treatment. Dhenin A; Samartzi V; Lejeune S; Seront E BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767 [TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-Induced Pancytopenia: A Case Report. Atwal D; Joshi KP; Ravilla R; Mahmoud F Perm J; 2017; 21():17-004. PubMed ID: 28746020 [TBL] [Abstract][Full Text] [Related]
8. Case report: reinitiating pembrolizumab treatment after small bowel perforation. Beck TN; Kudinov AE; Dulaimi E; Boumber Y BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-induced colitis: Could it be ulcerative colitis? Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419 [No Abstract] [Full Text] [Related]
10. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920 [No Abstract] [Full Text] [Related]
11. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab]. Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P Therapie; 2018; 73(3):291-293. PubMed ID: 29203065 [No Abstract] [Full Text] [Related]
12. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; Corrêa L; Buzaid AC J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A; Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178 [TBL] [Abstract][Full Text] [Related]
14. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S Eur J Cancer; 2019 May; 112():94-97. PubMed ID: 30954716 [No Abstract] [Full Text] [Related]